Jenny Seligmann, Professor of Gastrointestinal Oncology at the University of Leeds, shared a post on LinkedIn:
“Very proud of our fellow Jordan Appleyard presenting the analysis of HER3 expression in the FOxTROT trial in San Francisco.
High HER3 expression associated with panitumumab DFS and OS benefit when added to neoadjuvant FOLFOX in locally advanced colon cancer.
Smashed it!”
More posts featuring ASCO GI26.